Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Immuron Limited has reported the results of a recent clinical trial focusing on a new oral therapy targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC). The trial, conducted by the US Naval Medical Research Command (NMRC), showed promising results of 10.4% protective efficacy against campylobacteriosis in volunteers. This study does not impact Immuron's plan for Travelan®, with exciting Phase 3 clinical trials set to begin in the second half of 2025. 

Investors are encouraged to explore the clinical trial details available online and reach out with any questions they may have about the company's recent developments and future plans. Immuron continues to strive towards developing innovative solutions to combat infectious diseases and improve global health. 

Immuron Limited has reported the results of a recent clinical trial focusing on a new oral therapy targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC). The trial, conducted by the US Naval Medical Research Command (NMRC), showed promising results of 10.4% protective efficacy against campylobacteriosis in volunteers. This study does not impact Immuron's plan for Travelan®, with exciting Phase 3 clinical trials set to begin in the second half of 2025. <br/><br/>The company remains committed to its commercialization strategy for Travelan® and is actively involved in various clinical studies to evaluate the efficacy of their products. The NMRC-developed vaccine used in the study has shown great potential in producing hyperimmune products targeting specific pathogens. Further details of the study will be presented at an upcoming conference, providing more insights into the findings. <br/><br/>Investors are encouraged to explore the clinical trial details available online and reach out with any questions they may have about the company's recent developments and future plans. Immuron continues to strive towards developing innovative solutions to combat infectious diseases and improve global health. <br/><br/>For more information, you can contact Steven Lydeamore, the Chief Executive Officer of Immuron Limited, at +61 (0)3 9824 5254 or steve@immuron.com. Stay informed about the company's progress and upcoming presentations by visiting our official website at http://www.immuron.com.

NMRC Reports Results for Campylobacter Clinical Study

Summary